WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO2011146712) COMBINATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/146712    International Application No.:    PCT/US2011/037146
Publication Date: 24.11.2011 International Filing Date: 19.05.2011
A01N 43/54 (2006.01), A61K 31/505 (2006.01), A61K 31/517 (2006.01)
Applicants: GLAXOSMITHKLINE LLC [US/US]; One Franklin Plaza 200 North 16th Street Philadelphia, PA 19102 (US) (For All Designated States Except US).
GILMER, Tona, M. [US/US]; (US) (For US Only).
KUMAR, Rakesh [US/US]; (US) (For US Only)
Inventors: GILMER, Tona, M.; (US).
KUMAR, Rakesh; (US)
Agent: DUSTMAN, Wayne, J.; GlaxoSmithKline Corporate Intellectual Property, UW2220 709 Swedeland Road, P.O. Box 1539 King of Prussia, PA 19406-0939 (US)
Priority Data:
61/347,081 21.05.2010 US
61/374,343 17.08.2010 US
Abstract: front page image
(EN)The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-Chloro-4-[(3- fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4- quinazolinamine, or a pharmaceutically acceptable hydrate and/or salt thereof, and N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy;-2,4,7-trioxo-3,4,6,7- tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof.
(FR)La présente invention concerne un procédé de traitement d'un cancer chez l'homme et des combinaisons pharmaceutiques utiles dans un tel traitement. En particulier, le procédé concerne un procédé de traitement d'un cancer qui comprend l'administration, à un être humain qui en a besoin, de N-{3-chloro-4-[(3-fluorobenzyl)oxy]phényl}-6-[5-({[2-(méthanesulfonyl)éthyl]amino}méthyl)-2-furyl]-4-quinazolinamine, ou d'un hydrate et/ou sel de qualité pharmaceutique de celle-ci, et de N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phényl}acétamide, ou d'un sel ou solvate de qualité pharmaceutique de celui-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)